Dimenhydrinate
Dimenhydrinate (dimenhydrinate) is a small molecule pharmaceutical. Dimenhydrinate was first approved as Dimenhydrinate on 1982-01-01. It is used to treat motion sickness, nausea, vertigo, and vomiting in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dimenhydrinate (discontinued: Dimenhydrinate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| airmit ace | C200263 | 2023-12-01 |
| dimenhydrinate | ANDA | 2024-10-11 |
| dramamine | C200263 | 2024-10-25 |
| dramamine - n | C200263 | 2024-10-25 |
| dramamine dramamine, travel basix | C200263 | 2024-02-16 |
| dramamine for kids | OTC monograph final | 2021-04-09 |
| dramamine less drowsy | C200263 | 2024-01-05 |
| dramamine orange | OTC monograph final | 2017-12-06 |
| dramamine original formula | C200263 | 2023-12-27 |
| driminate | C200263 | 2024-02-23 |
Show 6 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| vomiting | HP_0002013 | D014839 | R11.1 |
| nausea | HP_0002018 | D009325 | R11.0 |
| vertigo | — | D014717 | H81.39 |
| motion sickness | — | D009041 | T75.3 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1240 | Injection, dimenhydrinate, up to 50 mg |
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | 1 | 3 | 5 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | — | 2 | 2 | 5 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | 1 | — | 2 | 2 | 5 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | 1 | — | 1 | 2 | 4 |
| Vertigo | D014717 | — | H81.39 | — | — | 1 | 3 | — | 4 |
| Dizziness | D004244 | HP_0002321 | R42 | — | — | 1 | 3 | — | 4 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | 3 | 1 | 4 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | 1 | 3 | 4 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 2 | 1 | 3 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 2 | 1 | 3 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 1 | 1 | — | 2 | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | 2 | — | 2 | 4 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 2 | — | 1 | 3 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | 1 | 1 | — | — | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | — | 2 |
| Skin diseases | D012871 | — | L00-L99 | — | 1 | 1 | — | — | 1 |
| Avulsion fractures | D000071562 | — | — | — | 1 | 1 | — | — | 1 |
| Degloving injuries | D000069836 | — | — | — | 1 | 1 | — | — | 1 |
| Eczematous skin diseases | D017443 | — | — | — | 1 | 1 | — | — | 1 |
| Athletic injuries | D001265 | — | — | — | 1 | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | 3 | 5 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 2 | 1 | — | — | 1 | 3 |
| Dental implants | D015921 | — | — | 1 | 1 | — | — | 2 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | — | — | — | 1 |
| Drug eruptions | D003875 | — | — | 1 | 1 | — | — | — | 1 |
| Pneumothorax | D011030 | HP_0002108 | J93.11 | 1 | 1 | — | — | — | 1 |
| Hydropneumothorax | D006872 | — | J94.8 | 1 | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cicatrix | D002921 | HP_0100699 | L90.5 | 1 | — | — | — | 4 | 5 |
| Gingival recession | D005889 | — | K06.0 | 1 | — | — | — | 2 | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | 1 | — | — | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
| Tooth extraction | D014081 | — | — | 1 | — | — | — | — | 1 |
| Bone transplantation | D016025 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dehydration | D003681 | — | E86.0 | — | — | — | — | 5 | 5 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 4 | 4 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | — | 2 | 2 |
| Positron emission tomography computed tomography | D000072078 | — | — | — | — | — | — | 2 | 2 |
| Xerostomia | D014987 | — | K11.7 | — | — | — | — | 2 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 2 | 2 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | — | 2 | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 2 | 2 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 2 | 2 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 2 | 2 |
Show 78 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dimenhydrinate |
| INN | dimenhydrinate |
| Description | 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O |
Identifiers
| PDB | — |
| CAS-ID | 523-87-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200406 |
| ChEBI ID | — |
| PubChem CID | 10660 |
| DrugBank | DB00985 |
| UNII ID | JB937PER5C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Dimenhydrinate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,599 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,966 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use